Navigation Links
Collegium Pharmaceutical Announces Relocation to Massachusetts
Date:1/17/2013

of the development of this important product," said Michael Heffernan , CEO of Collegium. "It is becoming increasingly recognized that tamper-resistant, extended-release opioids play an important role in the fight against prescription pain medication abuse. Oxycodone DETERx® may offer a number of significant clinical advantages over currently marketed tamper-resistant opioids for the treatment of chronic pain."

About DETERx® Technology

The DETERx® drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide tamper-resistant properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastronomy tube, while maintaining the extended-release properties of the product. DETERx® technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. Oxycodone DETERx® (COL-003) is the first of a number of product candidates using the DETERx® platform.

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® formulation platform for the treatment of chronic pain. The DETERx® oral drug delivery technology provides extended-release delivery, unique tamper-resistant properties, and flexible dose
'/>"/>

SOURCE Collegium Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Collegium Pharmaceutical to Present at Piper Jaffrays 24th Annual Healthcare Conference
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
9. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
10. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
11. Icahn Issues Statement Regarding Amylin Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... physicians in achieving better outcomes for AF, ... venous thromboembolism patients, INDIANAPOLIS, March 19 ... equipment and supplies for all long-term,warfarin users who monitor their own ... System for Patient Self-Testing. This,expansion opens the door to increased patient ...
... (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced ... patients with Type 1 diabetes,in a Phase 2 ... TPM/Insulin. The lead clinical investigators of the trial ... Royal Brisbane and,Women,s Hospital, and William Hsu, who ...
Cached Medicine Technology:Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home 2Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home 3Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home 4Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes 2Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes 3
(Date:4/22/2014)... for low-income patients may ease the financial burden ... patient health, researchers have concluded. , A study ... avoid costs associated with insurance administration can help ... and emergency room visits, according to Mark Agee, ... The researchers estimated that the major hospital in ...
(Date:4/22/2014)... 2014) The International Communication Association will hold ... Washington. The theme of the 2014 conference will ... networked and digital society. , Featuring over 2,300 ... 2,200 Communication scholars representing over 40 countries, the ... conference in the world. This year,s conference features ...
(Date:4/22/2014)... health care spending, a new RAND study concludes that ... pharmaceutical companies and device makers to develop products that ... technologies and their use, a new study suggests the ... devices get created in the first place. The aim ... little loss of health as possible and to ensure ...
(Date:4/22/2014)... of all patients diagnosed with non-small cell lung cancer ... this high percentage, these elderly patients are not well ... data has made it difficult to reach evidence based ... the Elderly Task Force and Lung Cancer Group along ... an expert opinion on managing treatment for elderly patients ...
(Date:4/22/2014)... but their total brain size suggests they have ... squirrel, according to a new study of 36 ... to zebra finches. , Scientists at Duke University, ... other research institutions collaborated on this first large-scale ... the study as the ability to inhibit powerful ...
Breaking Medicine News(10 mins):Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Brain size matters when it comes to animal self-control 2Health News:Brain size matters when it comes to animal self-control 3
... 8 With rising food costs, many,families are economizing ... back,on is nutrition. At about 25 cents per 8-ounce ... penny than almost any other beverage option in the,supermarket ... vitamin D,that are important for the entire family. To ...
... 8 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... presenting at the upcoming 27th Annual J.P. Morgan Healthcare Conference. ... to begin on Wednesday, January 14, 2009 at 4:00 p.m. PT. ... Hotel in San Francisco, CAJanuary 11-15, 2009. , ...
... 8 Paul Spiegelman, author of Why Is ... knows a few things about how to infuse joy into ... from a proven track-record of success. Spiegelman,s commitment to creating ... the company he founded - The Beryl Companies - seven ...
... With its acclaimed debut in 2007,MyHealthArchive revolutionized every ... by bringing the process into the digital age. ... record-keeping, allowing,subscribers to take charge of their health ... under their own centralized control and energizing their ...
... 8 /PRNewswire-FirstCall/ - StonePoint Global Brands Inc. (TSXV:SPG) ... Oxford, has launched its upgraded in-room merchandising system ... packaging options, upgraded food selections, Room Service kits ... numerous other product and service improvements. , ...
... 8 Human Genome Sciences, Inc. (Nasdaq: HGSI ) ... results of ACHIEVE 2/3, its Phase 3 trial of Albuferon(R) (albinterferon alfa-2b) ... http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) , , The ... on Monday, December 8, 2008 at 8:15 am Eastern Time. , ...
Cached Medicine News:Health News:Milk is One Beverage Jackson Can't Afford to Keep Off the Grocery List 2Health News:Milk is One Beverage Jackson Can't Afford to Keep Off the Grocery List 3Health News:Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th 2Health News:'Smiling' Author Reveals 12 Ways To Make Your Workplace Merry This Holiday Season 2Health News:'Smiling' Author Reveals 12 Ways To Make Your Workplace Merry This Holiday Season 3Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 2Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 3Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 4Health News:StonePoint Announces Completion of Test Market and Launch of New Program 2Health News:Human Genome Sciences to Sponsor Conference Call 2
Lacrimal cannula blunt tip with 0.3 mm side port, straight....
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
Solo-care is a multi-purpose solution for cleaning, rinsing, disinfection and storing soft contact lenses....
Graether Collar Button micro iris retractor....
Medicine Products: